Biotech venture capital: Recovery gains momentum in 2025-2026
Biotech venture capital entered a period of recalibration in 2025, marked by significant market volatility that disrupted funding for many companies. After a strong 2024, when biotech VC surpassed pre-pandemic levels with early venture rounds reaching $15.5 billion, the environment became more challenging as macroeconomic headwinds, NIH funding cuts, and regulatory uncertainty weighed on sentiment.
Despite these pressures, the back half of 2025 showed clear recovery. Venture financing deal value jumped 70.9% from Q2 to Q3 2025, and roughly 60% of all biotech VC funding was announced in the second half of the year. Megarounds defined the landscape: Kailera Therapeutics raised an extraordinary $600 million Series B for its AI-driven obesity therapeutics platform. The top 10 private biotech rounds in 2025 brought in nearly $4 billion collectively.
The "haves and have-nots" dynamic intensified. Companies with strong clinical data, experienced management teams, and platforms in high-demand areas (obesity, neurodegeneration, oncology) attracted outsized capital, while others struggled. Investors demanded more third-party validation before committing.
The intersection of AI and biotech remained one of the most active areas. Startups using machine learning for drug discovery, computational biology, and protein design attracted capital from both traditional life sciences VCs and tech-native investors.
Top biotech venture capital firms right now
The biotech investment landscape continues to be led by deep-domain specialists. ARCH Venture Partners, OrbiMed, Sofinnova Ventures, Flagship Pioneering, and Frazier Life Sciences led many of the largest deals. ARCH co-led a $200 million round for Tenvie Therapeutics, while Frazier closed one of the largest biotech venture funds in recent years.
Corporate venture capital from pharma giants expanded significantly. Bristol Myers Squibb, Sanofi, Eli Lilly, Merck, and Roche all ramped up VC activity. Sanofi Ventures co-led SpliceBio's $135 million Series B for gene therapy – exemplifying partnerships that provide both capital and a commercial pathway.
Tech VCs continue to cross into biotech. Andreessen Horowitz's Bio Fund and NEA back AI-driven drug discovery platforms, reflecting the growing importance of computational approaches in modern therapeutics.
In Europe, the biotech funding gap persists. Of the 67 EU-based biotech companies that went public over the past six years, 66 did so outside the EU. A new European Life Sciences Coalition was formed in early 2026 to attract more venture capital. Founders in Germany, France, and Sweden should consider US listings or cross-border VC partnerships.
Biotech investment outlook for 2026
The outlook for 2026 is cautiously optimistic, supported by interest rate cuts, improving exits, and sustained M&A from pharma companies facing patent cliffs.
The IPO window is reopening. M&A activity reached $43.2 billion in Q3 2025, including multiple billion-dollar-plus acquisitions. This liquidity flows back into the venture ecosystem.Key therapeutic areas attracting investment include obesity (the GLP-1 revolution), neurodegeneration, oncology, and gene therapy. AI-driven drug discovery remains a top theme, with investors backing platforms that accelerate target identification through clinical development.
